比较头孢曲松/阿米卡星与头孢他啶/阿米卡星作为中性粒细胞减少患者发热性发作初始治疗的随机临床试验。
Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
作者信息
Yataganas X, Rombos Y, Vayopoulos G, Meletis J, Avlami A
机构信息
University of Athens Medical School, First Department of Internal Medicine, Laikon General Hospital, Greece.
出版信息
Chemotherapy. 1991;37(5):376-81. doi: 10.1159/000238882.
Neutropenic patients with underlying hematologic (usually malignant) diseases were randomized to receive either 2 g ceftriaxone once daily +0.5 g amikacin or 2 g ceftazidime twice daily +0.5 g amikacin b.i.d. when fever was higher than 38 degrees C and granulocyte counts less than 0.5 x 10(9)/l. 25 patients were included in each treatment group. Successful outcome of treatment was observed in 28 (13/15) and in an additional 5 (2/3) patients after modification of the therapy. Tolerability was excellent in both groups.
患有潜在血液系统疾病（通常为恶性）的中性粒细胞减少患者，在发热高于38摄氏度且粒细胞计数低于0.5×10⁹/L时，被随机分为两组，一组接受每日一次2克头孢曲松+0.5克阿米卡星治疗，另一组接受每日两次2克头孢他啶+0.5克阿米卡星治疗。每个治疗组纳入25例患者。治疗方案调整后，28例（13/15）患者和另外5例（2/3）患者治疗成功。两组的耐受性均良好。
Zotero 插件